ValuEngine upgraded shares of Forward Pharma A/S (NASDAQ:FWP) from a sell rating to a hold rating in a research note published on Saturday morning.
Several other analysts have also recently commented on the company. Zacks Investment Research raised Forward Pharma A/S from a hold rating to a buy rating and set a $22.00 price target for the company in a report on Wednesday, April 5th. Jefferies Group LLC set a $22.00 price objective on Forward Pharma A/S and gave the company a hold rating in a research note on Tuesday, April 18th. Leerink Swann set a $28.00 price objective on Forward Pharma A/S and gave the company a buy rating in a research note on Monday, April 3rd. Finally, JMP Securities downgraded Forward Pharma A/S from an outperform rating to a market perform rating in a research note on Monday, April 3rd. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus target price of $24.00.
Forward Pharma A/S (FWP) traded up 8.18% during mid-day trading on Friday, hitting $21.96. The stock had a trading volume of 70,493 shares. Forward Pharma A/S has a 12-month low of $14.89 and a 12-month high of $33.00. The stock has a 50-day moving average price of $19.74 and a 200 day moving average price of $22.41. The firm’s market cap is $1.04 billion.
Institutional investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC bought a new position in Forward Pharma A/S during the fourth quarter valued at $5,918,000. NJ State Employees Deferred Compensation Plan bought a new position in Forward Pharma A/S during the first quarter valued at $323,000. Eqis Capital Management Inc. bought a new position in Forward Pharma A/S during the first quarter valued at $346,000. MARSHALL WACE ASIA Ltd bought a new position in Forward Pharma A/S during the first quarter valued at $612,000. Finally, Marshall Wace North America L.P. bought a new position in Forward Pharma A/S during the first quarter valued at $612,000. 22.24% of the stock is owned by hedge funds and other institutional investors.
Forward Pharma A/S Company Profile
Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.
To view ValuEngine’s full report, visit ValuEngine’s official website.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230856/forward-pharma-as-fwp-lifted-to-hold-at-valuengine.html
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.